Central Insulin-like Growth Factor-1 Treatment Enhances Working and Reference Memory by Reducing Neuroinflammation and Amyloid Beta Deposition in a Rat Model of Sporadic Alzheimer's Disease.

Pharmaceuticals (Basel) · 2025 · PMC12030085 · PMID 40283962

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

At days 91 and 92 post-injection (days 2 and 3 of the MWM) in the STZIGF-1 group, the latency was shorter compared to the STZSAL group, but the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.